Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Guselkumab could offer hope for psoriatic arthritis patients resistant to TNF inhibitors

By Brian Buntz | June 13, 2023

Logo of Janssen which is Johnson & Johnson’s pharmaceutical segmentJanssen continues to strengthen the case that its interleukin-23 inhibitor TREMFYA (guselkumab) offers promise to many patients with psoriatic arthritis (PsA).

The company’s phase 3b COSMOS clinical trial involving 189 patients with active PsA and an inadequate response to one to two previous tumor necrosis factor (TNF) inhibitors, guselkumab showed sustained improvements in measures of minimal disease activity (MDA) over 48 weeks of treatment. TNF inhibitors are a class of medications that target and suppress the overproduction of the inflammatory protein TNF, making them a common treatment option for autoimmune diseases such as PsA.

The IL-23 inhibitor guselkumab provides a treatment alternative, recording sustained improvements in measures of minimal disease activity (MDA) over 48 weeks of treatment. In particular, 60 to 80% of patients achieved MDA across various measures.

Beyond guselkumab, another approved IL-23 inhibitor for the treatment of psoriatic arthritis (PsA) is AbbVie’s Skyrizi (risankizumab). The FDA gave the green light for Skyrizi’s use in psoriasis in 2019, and subsequently extended its approval for PsA as well in early 2022.

COSMOS trial of guselkumab fared well in difficult-to-treat patients

One of the principal investigators of COSMOS, Dr. Carlo Selmi, provided an overview of the study, noting that it focused on patients who had become resistant to multiple biologics, making them challenging to treat.

“Predominantly, psoriatic arthritis is treated with biologics, and TNF alpha inhibitors remain the first-line treatment for about 90% of patients,” said Selmi, who is the director of the residency school of emergency medicine at Humanitas University.

Such patients often become resistant to multiple biologics, “making them the toughest to treat,” Selmi said. The discovery of an alternative mechanism, IL-23 inhibition, is promising news for these patients, Selmi said.

IL-23 inhibition offers new treatment approach for challenging cases

Selmi explained that, in contrast to rheumatoid arthritis, psoriatic arthritis exhibits a more complex phenotype. Physicians treating rheumatoid arthritis primarily focus on factors like joint counts, which evaluate swollen or tender joints, and patient perception, assessing the patient’s view of their disease activity. They also consider inflammatory markers such as C-reactive protein, a protein generated by the liver as a result of inflammation, and ESR, the erythrocyte sedimentation rate, a blood test analyzing the settling rate of red blood cells in a test tube, signifying inflammation.

In PsA, researchers must weigh factors beyond peripheral arthritis such as dactylitis, enthesitis and the involvement of skin and nails. The MDA index used in COSMOS provided a comprehensive measure of disease activity, Selmi noted. The index is “significantly more relevant to the patient than, say, a joint count or other indices like the ACR response borrowed from rheumatoid arthritis,” he noted.

Predictors of achievement of patient-reported Minimal Disease Activity (MDA) domains at Week 48 in patients with Psoriatic Arthritis (PsA) inadequately responding to TNF inhibitors, treated with guselkumab. The table outlines different baseline variables (BL variables) and how they influenced different MDA parameters, including HAQ-DI (Health Assessment Questionnaire – Disability Index) ≤0.5, Patient pain ≤15, Patient Global Assessment (PtGA) ≤20, and Tender Joint Count (TJC) ≤1. The predictors are reported as odds ratios, hazard ratios, or simple measures with 95% confidence intervals.

Predictors of achievement of patient-reported Minimal Disease Activity (MDA) domains at Week 48 in patients with Psoriatic Arthritis (PsA) inadequately responding to TNF inhibitors, treated with guselkumab in the COSMOS study. The table outlines different baseline variables (BL variables) and how they influenced different MDA parameters, including HAQ-DI (Health Assessment Questionnaire – Disability Index) ≤0.5, Patient pain ≤15, Methotrexate (MTX) Use, Patient Global Assessment (PtGA) ≤20, Tender Joint Count (TJC) ≤1 and the FACIT fatigue score, a scale is a questionnaire used to assess levels of fatigue in patients. The predictors are reported as odds ratios, hazard ratios, or simple measures with 95% confidence intervals.

Complexity of psoriatic arthritis and the MDA index in COSMOS trial

Taking into account the complexity of psoriatic arthritis, the COSMOS trial assessed guselkumab’s effectiveness on a range of response rates and patient experiences. The overall response rates at weeks 24 and 48 across varied domains were notable. These included the Psoriasis Area and Severity Index (PASI), Leeds Enthesitis Index (LEI), swollen joint count (SJC) and Health Assessment Questionnaire – Disability Index (HAQ-DI), among others. Interestingly, physician-reported domains (LEI, PASI and SJC) seemed to demonstrate faster improvements than patient-driven ones. “What’s interesting about the COSMOS trial findings is that more objective measures of disease, such as the swollen joint count, were met first, as compared to the patient’s perception,” Selmi said. “However, this doesn’t diminish the importance of patient-reported outcomes. It’s about striking the right balance between objective measures and the patient’s experience.”

Despite the trial findings indicating that physicians noted objective measures of disease before patients did, Selmi emphasized the need for a balanced approach that factors in patient-reported outcomes. Selmi noted, “The safety profile of guselkumab is reassuring, especially in terms of infections, a concern whenever we use an immunosuppressive type of treatment.” He also said the lack of signals for major infections, major cardiovascular events, and neoplastic growth were comforting.

Guselkumab’s safety profile and implications for patient outcomes

The COSMOS trial’s findings also highlighted predictors of non-achievement of MDA, such as baseline domain scores, fatigue, and methotrexate use. This information could be instrumental in making more informed treatment decisions for individual patients. As data from the Phase 3 studies continue to emerge, it appears that patients treated with TREMFYA can achieve long-term efficacy across PsA domains, including sustained improvements in health-related quality of life (HRQoL). The COSMOS trial also discovered predictors of non-achievement of MDA. These include baseline domain scores, fatigue, and methotrexate use.

“And we now know that interleukin 23 is crucial also to those conditions,” Selmi added. “And in fact, interleukin 23 blockers have now been even approved that are being evaluated in phase 3 trials for both Crohn’s and ulcerative colitis.”

In PsA treatment, traditionally only a minority of patients on biologic therapy have achieved sustained MDA. TREMFYA offered sustained improvement across all MDA domains over 48 weeks for adult patients who showed insufficient responses to one or two TNFis.


Filed Under: Biologics, clinical trials, Drug Discovery, Immunology, Rheumatology
Tagged With: clinical trials, guselkumab, interleukin-23 inhibitor, psoriatic arthritis., Rheumatology, TNF inhibitors, Tremfya
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Rosnilimab phase 2b trial shows promise in treating RA
rosnilimab
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance 
Zai Lab
Zai Lab’s unified approach to tackling cancer, autoimmune, and neurological diseases
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE